Implementation of the Clinical Trials Regulation in the EU and EEA
The Clinical Trials Information System will become mandatory for all authorisation application for a clinical trial in the EU on 31 January 2023
Oncology News
ESMO oncology news aims to keep you up to date with the developments that affect you and your daily practice.
Make sure you check these pages frequently, or sign up to our newsletter! To sign up for ESMO newsletters, create a myESMO account here and select the newsletters you’d like to receive.
1616 results
FDA Grants Accelerated Approval to Mosunetuzumab-axgb for Relapsed or Refractory Follicular Lymphoma
Evidence for efficacy is based on the results from the GO29781 study
Adagrasib Shows Promising Activity as Monotherapy, Even Greater in Combination with Cetuximab, and Reversible Side Effects in Patients with Previously Treated KRAS G12C–Mutated mCRC
Findings from the ongoing KRYSTAL-1 phase I/II study in patients with metastatic colorectal cancer with a KRAS G12C mutation
Sotorasib Shows Promising Activity and Acceptable Safety in Patients with Previously Treated KRAS p.G12C–Mutated Advanced Pancreatic Cancer
Findings from the phase I and phase II portions of the CodeBreaK 100 study
FDA Approves Updated Drug Labelling Including New Indications and Dosing Regimens for Capecitabine Tablets
It is the first drug to receive a labelling update under Project Renewal
EMA Recommends Extension of Therapeutic Indications for Durvalumab and Adopts a Positive Opinion for Tremelimumab
New indications concern the combination treatment of metastatic non-small cell carcinoma and of advanced or unresectable hepatocellular carcinoma
EMA Recommends Extension of Therapeutic Indications for Trastuzumab Deruxtecan
New indication concerns the treatment of unresectable or metastatic HER2-low breast cancer
Mutational Patterns Drive Metastatic Aggressiveness of Appendiceal Adenocarcinomas
Different molecular subtypes of appendiceal adenocarcinomas have distinct clinical and biological behaviours that may be useful in guiding therapeutic decision
Reduction Not Only in Recurrences, but Also in Mortality, Observed for Exemestane Plus Ovarian Function Suppression in Premenopausal Women with Hormone Receptor Positive EBC
Findings from a combined analysis of SOFT-TEXT after a median follow-up of 13 years
Efficacy of a Bispecific Monoclonal Antibody Glofitamab for Relapsed or Refractory DLBCL
Glofitamab induces durable complete responses in patients with relapsed or refractory diffuse large B-cell lymphoma
FDA Grants Accelerated Approval to Adagrasib for KRAS G12C-Mutated NSCLC
FDA also approved the QIAGEN therascreen KRAS RGQ PCR kit (tissue) and the Agilent Resolution ctDx FIRST Assay (plasma) as companion diagnostics
FDA Grants Approval to Atezolizumab for Alveolar Soft Part Sarcoma
Evidence for efficacy is based on the results from the Study ML39345